Russia Nanotech Giant Invests $26 Million For 'Unique' Cancer, MS Drugs
This article was originally published in PharmAsia News
Executive Summary
Russia's Rusnano nanotech specialist said it would spend as much as $26 million, possibly with a Russian biotech and U.S. pharma as co-funders, on a venture for cancer and multiple sclerosis drug development.